4D Molecular Therapeutics FDMT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -220.1%+883,806pp | -204.5%+507,474pp | -191,982.5%+275,729pp | -667,654.5%-667,006pp | -884,026.1%-883,436pp | |
| EBITDA margin | -214.6%+864,112pp | -199%+494,904pp | -188,170.8%+266,599pp | -654,009.1%-653,383pp | -864,326.1%-863,757pp | |
| Returns | ||||||
| Return on invested capital | -51.1%+7.0pp | -40.9%+40.9pp | -62.9%+10.4pp | -56.5%-5.8pp | -58.2%-9.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×— | 0.2×+0.2× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 9.3×-3.0× | 9.4×-5.5× | 8.4×-8.9× | 8.7×-19.7× | 12.4×-20.3× | |
| Quick ratio | 9.3×-3.0× | 9.4×-5.5× | 8.4×-8.9× | 8.7×-19.7× | 12.4×-20.3× | |
| Cash ratio | 1.7×-3.3× | 1.4×-3.8× | 1.3×-5.1× | 2.2×-7.5× | 5×-11.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.64-21.2% | $8.73-7.8% | $6.57-33.9% | $7.53-29.3% | $8.43-30.9% | |
| Valuation | ||||||
| Market capitalization | $602.22M+215% | $428.51M+66.4% | $405.84M-32.1% | $185.3M-84.0% | $149.56M-90.5% | |
| Enterprise value | $550.27M+574% | $389.69M+194% | $379.55M-12.7% | $131.22M-86.7% | $39.88M-97.0% | |
| Price / sales | 6.8×-8,306× | 5×-6,954× | 3,382×-13,218× | 5,615.1×+5,558× | 6,502.5×+6,426× | |
| Price / book | 1.3×+0.9× | 0.8×+0.3× | 1.1×0.0× | 0.4×-1.5× | 0.3×-2.3× | |
| EV / sales | 6.2×-3,544× | 4.6×-3,583× | 3,162.9×-8,918× | 3,976.3×+3,928× | 1,734.1×+1,670× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do 4D Molecular Therapeutics's ratios come from?
- Every ratio is computed from 4D Molecular Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
